Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Myovant Sciences Ltd 50 BROADWAY 7TH FLOOR LONDON X0 SW1H 0DB GBR

myovant.com P: 44-20-7400-3351

Description:

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.

Key Statistics

Overview:

Market Capitalization, $K 2,623,400
Enterprise Value, $K 2,547,920
Shares Outstanding, K 97,235
Annual Sales, $ 230,970 K
Annual Net Income, $ -205,980 K
Last Quarter Sales, $ 100,230 K
Last Quarter Net Income, $ -57,630 K
60-Month Beta 2.17
% of Insider Shareholders 1.90%
% of Institutional Shareholders 30.62%
Float, K 95,388
% Float 98.10%
Short Volume Ratio 0.38

Growth:

1-Year Return 118.99%
3-Year Return 278.93%
5-Year Return 44.51%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -30.59%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.59 on 01/26/23
Next Earnings Date 01/25/23
Earnings Per Share ttm -1.91
EPS Growth vs. Prev Qtr -25.53%
EPS Growth vs. Prev Year 13.24%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MYOV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -39.36%
Profit Margin % -89.18%
Debt/Equity -0.64
Price/Sales 11.36
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -5.74
Interest Coverage -13.38
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar